Radiological Progression | |||
---|---|---|---|
≥ 75th Percentile† | 75–25th Percentile | ≤ 25th Percentile | |
Improvement of core set at 12 weeks | |||
No. cases | 14 | 26 | 15 |
Swollen joint count | |||
Basal | 12.2 ± 6.9 | 9.4 ± 6.6 | 8.9 ± 3.9 |
At 12 weeks | 9.6 ± 6.5** | 4.7 ± 4.3 | 4.3 ± 3.3 |
% decrease†† | 21.6 | 50.6 | 51.7 |
CRP | |||
Basal | 6.0 ± 2.9* | 4.4 ± 4.5 | 1.8 ± 2.1** |
At 12 weeks | 5.5 ± 3.4** | 3.1 ± 3.5 | 0.7 ± 0.9** |
% decrease†† | 8.8 | 28.2 | 62.6 |
Patient’s estimation of pain | |||
Basal | 70.4 ± 22.4 | 69.5 ± 25.1 | 57.2 ± 23.1# |
At 12 weeks | 59.0 ± 26.2** | 42.3 ± 21.5 | 26.0 ± 16.5** |
% decrease†† | 16.1 | 39.2 | 54.5 |
Characteristics of 3 groups | |||
Initial treatment (MTX, BUC, MTX+BUC, respectively) | 5, 7, 2 | 11, 6, 9 | 3, 7, 5 |
No. cases, initial DMARD regimens changed (%)††† | 8 (57.1)** | 6 (23.1) | 1 (6.7)* |
Total Sharp score at start | 24.9 ± 15.0# | 19.8 ± 16.0 | 10.9 ± 8.49* |
Increase of total Sharp score during 96 weeks | 60.0 ± 28.1*** | 17.3 ± 7.4 | 3.12 ± 3.12*** |
HLA-DRB1*0405-positive, % | 85.7# | 61.5 | 53.3 |
RF-positive, % | 100.0 | 92.3 | 80.0 |
Anti-CCP antibody-positive, % | 90.0 | 95.7 | 80.0 |
↵† Progression of articular destruction during 96 weeks is greater than the 75th percentile of the cohort.
↵†† Percentage decrease from mean of initial values to mean of 12 week values.
↵††† Regimen was changed when ACR20 was not achieved after 24 weeks.
↵# p < 0.1 vs cases other than this group;
↵* p < 0.05 vs cases other than this group;
↵** p < 0.01 vs cases other than this group;
↵*** p < 0.0001 vs cases other than this group.